Theriva Biologics to Join A.G.P. Virtual Healthcare Conference

ROCKVILLE, Md., May 14, 2024 – Theriva™ Biologics (NYSE American: TOVX), a company focused on developing therapeutics aimed at treating cancer and related diseases with significant unmet needs, has announced that its management team will provide a corporate update and participate in a fireside chat at the A.G.P. 2024 Virtual Healthcare Conference.

A.G.P. 2024 Virtual Healthcare Conference
- Format: Fireside Chat
- Date: Tuesday, May 21, 2024
- Time: 7:30 AM ET
- Webcast: Click here

About Theriva™ Biologics, Inc.
Theriva™ Biologics is a clinical-stage company that is advancing a portfolio of therapeutics designed to address cancer and related diseases. The company is working on a novel oncolytic adenovirus platform that can be delivered intravenously, intravitreally, and antitumorally. This platform aims to induce tumor cell death, enhance the effectiveness of co-administered cancer therapies, and stimulate a strong, long-lasting anti-tumor immune response.

Leading Candidates
1. VCN-01: An oncolytic adenovirus that selectively targets and replicates within tumor cells. VCN-01 aims to break down the tumor stroma, a physical and immunosuppressive barrier that can impede cancer treatment.

2. SYN-004 (ribaxamase): This candidate is designed to degrade certain intravenous beta-lactam antibiotics within the gastrointestinal tract. It aims to protect the microbiome from damage, thereby preventing the overgrowth of harmful organisms like vancomycin-resistant Enterococci (VRE). This mechanism is also intended to reduce the incidence and severity of acute graft-versus-host disease (aGVHD) in patients undergoing allogeneic hematopoietic cell transplants (HCT).

3. SYN-020: A recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under current Good Manufacturing Practice (cGMP) conditions. It is intended to treat both local gastrointestinal (GI) and systemic diseases.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!